$69.56
1.62% day before yesterday
Nasdaq, Dec 05, 10:06 pm CET
ISIN
US03940C1009
Symbol
ACLX

Arcellx Stock price

$69.56
-17.95 20.51% 1M
+3.31 5.00% 6M
-7.13 9.30% YTD
-16.86 19.51% 1Y
+50.09 257.27% 3Y
+54.56 363.73% 5Y
+54.56 363.73% 10Y
+54.56 363.73% 20Y
Nasdaq, Closing price Fri, Dec 05 2025
+1.11 1.62%
ISIN
US03940C1009
Symbol
ACLX
Industry

Key metrics

Basic
Market capitalization
$4.0b
Enterprise Value
$3.6b
Net debt
positive
Cash
$461.4m
Shares outstanding
57.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
112.0 | 89.4
EV/Sales
99.2 | 79.1
EV/FCF
negative
P/B
9.1
Financial Health
Equity Ratio
63.9%
Return on Equity
-23.6%
ROCE
-45.1%
ROIC
-187.1%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$35.9m | $45.0m
EBITDA
$-235.7m | $-242.1m
EBIT
$-242.6m | $-248.2m
Net Income
$-217.9m | $-238.6m
Free Cash Flow
$-201.2m
Growth (TTM | estimate)
Revenue
-77.0% | -58.3%
EBITDA
-261.1% | -82.9%
EBIT
-249.4% | -80.4%
Net Income
-439.1% | -122.2%
Free Cash Flow
-5,735.3%
Margin (TTM | estimate)
Gross
-
EBITDA
-656.7% | -538.1%
EBIT
-675.7%
Net
-607.0% | -530.2%
Free Cash Flow
-560.4%
More
EPS
$-3.9
FCF per Share
$-3.5
Short interest
13.9%
Employees
163
Rev per Employee
$660.0k
Show more

Is Arcellx a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Arcellx Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a Arcellx forecast:

22x Buy
88%
3x Hold
12%

Analyst Opinions

25 Analysts have issued a Arcellx forecast:

Buy
88%
Hold
12%

Financial data from Arcellx

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
36 36
77% 77%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 110 110
31% 31%
307%
- Research and Development Expense 168 168
19% 19%
468%
-236 -236
261% 261%
-657%
- Depreciation and Amortization 6.83 6.83
65% 65%
19%
EBIT (Operating Income) EBIT -243 -243
249% 249%
-676%
Net Profit -218 -218
439% 439%
-607%

In millions USD.

Don't miss a Thing! We will send you all news about Arcellx directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arcellx Stock News

Neutral
Seeking Alpha
about 4 hours ago
Arcellx, Inc. (ACLX) Discusses Phase 2 iMMagine-1 Study Results and Multiple Myeloma Treatment Advances Transcript
Neutral
Business Wire
about 21 hours ago
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new positive data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple mye...
Neutral
Business Wire
19 days ago
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will host an Investor Relations event on Saturday, December 6, 2025 at 8:00 p.m. ET. The event will include a panel of clinician experts a...
More Arcellx News

Company Profile

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Gaithersburg, MD.

Head office United States
CEO Rami Elghandour
Employees 163
Founded 2014
Website www.arcellx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today